Ocular Therapeutix™ Announces Presentation at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS)

BEDFORD, Mass–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Jonathan
Talamo, M.D., Chief Medical Officer, will present at the Ophthalmology
Innovation Summit (OIS) at the American Society of Retina Specialists
(ASRS) on Monday, August 8, 2016, in San Francisco, CA.
Dr. Talamo will provide an update on the Company’s ongoing preclinical
development programs for its sustained release hydrogel technology being
developed to treat wet age-related macular degeneration (wet AMD) and
other retinovascular diseases. The Company is developing
sustained-release hydrogel-based drug delivery depots for intravitreal
injection that can be formulated with both small and large molecule
pharmaceuticals, with the goal of delivering sustained and therapeutic
levels of drugs to targeted ocular tissues for 4-6 months.
“We at Ocular Therapeutix continue to be encouraged by the results
emerging from work with our proprietary delivery platforms for high
molecular weight protein VEGF inhibitors and small molecule Tyrosine
Kinase Inhibitors,” stated Dr. Talamo. “I look forward to sharing these
interesting findings with my colleagues in San Francisco next week.”
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) is a biopharmaceutical company focused
on the development and commercialization of innovative therapies for
diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert), is in Phase 3 clinical development for
post-surgical ocular inflammation and pain and allergic conjunctivitis,
and in Phase 2 clinical development for dry eye disease. A third Phase 3
clinical trial is being conducted for post-surgical ocular inflammation
and pain. For glaucoma and ocular hypertension, the Company plans to
initiate the first of two OTX-TP (sustained release travoprost) Phase 3
clinical trials in the third quarter of 2016. Ocular Therapeutix is
evaluating sustained-release injectable drug depots for back-of-the-eye
diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the
development and regulatory status of the Company’s product candidates,
such as the Company’s expectations and plans regarding regulatory
submissions for and the timing and conduct of clinical trials of
DEXTENZA for post-surgical ocular inflammation and pain, including our
expectations regarding the pending NDA filed with the FDA, DEXTENZA™ for
the treatment of allergic conjunctivitis, DEXTENZA for dry eye disease
and OTX-TP for the treatment of glaucoma and ocular hypertension, the
ongoing development of the Company’s sustained release hydrogel depot
technology and the advancement of the Company’s other product
candidates, the potential utility of any of the Company’s product
candidates, the sufficiency of the Company’s cash resources and other
statements containing the words “anticipate,” “believe,” “estimate,”
“expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors. Such forward-looking statements involve substantial
risks and uncertainties that could cause the Company’s clinical
development programs, future results, performance or achievements to
differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among
others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that receives
regulatory approval, the initiation and conduct of clinical trials,
availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of the
date of this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some
point in the future, the Company specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date
of this release.